Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by Dumitrita RUGINA
Total Records ( 3 ) for Dumitrita RUGINA
  Carmen SOCACIU , Monica TRIF , Dumitrita RUGINA , Adela PINTEA and Simion ASTILEAN
  We aimed to demonstrate that the functionalization of nanocolloids of Au in vitro, induce the formation of conjugated forms (with glutathion) which can affect the cellular activity, as tested on Saccharomyces cerevisiae and RPE cells. The cell line relevant for macular degeneration, type RPE (line D407) proved to be more sensitive to nanogold and conjugated forms. By microscopy we demonstrated the cell capacity to form a monolayer, as a prove of their proliferation and viability, as well in the presence of free AuC, glutathione, but also in the presence of conjugated forms AuC-glutathion. AuC-glutathion conjugate, at pH 5.6 (optimum for cell growth) is stable and can have effect on cellular activity, with impact on proliferation and viability. Obviously, the interaction of AuC and AuC-glutation conjugate with cell components may have effects on cell proliferation and rapid metabolization in presence of appropriate enzymes. (e.g. Glutation peroxidase). Alternative and complementary studies are needed to show the localization of AuC and AuC-glutathion conjugate at cellular level, by microscopy and spectroscopy. It is possible that, inside cell, AuC to conjugate other biomolecules, with a higher stability and affinity, comparing to glutathion.
  Dumitrita RUGINA , Simona VICAS , Mariana PETRAN , Adela PINTEA , Andrea BUNEA and Carmen SOCACIU
  In Europe, mistletoe extract (Viscum album) is widely used as complementary cancer therapies. The main active component of mistletoe extract is glycoprotein, lectin, that exhibit cytotoxic effects and immunomodulatory activities. The aim of this study was to show if the mistletoe extract, rich in phenolic acids presents anti-carcinogenic potential on A2780 tumor ovarian cells. In the first part of this study, using high performance liquid chromatography (HPLC) analysis we characterized phenolic acid content of mistletoe growing on Malus domestica. And, in the second part, we investigated whether by apoptosis on ovarian tumor cell line A2780 if anti-cancer effect of this extract mistletoe is induced. Cell proliferation was assessed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenylt-etrazolium bromide (MTT) assay. The A2780 cell viability was inhibited to 87% by 50 μg/ml mistletoe extract treatment, and to 79% at 110 μg/ml extract concentration. To find out the apoptotic cell death, 4, 6-diamidino-2-phenylindole (DAPI) staining was performed. Cells treated with mistletoe (110 μg/ml) for 24 h displayed typical morphological features of apoptotic cells, with condensed and fragmented nuclei. Fluorimetric method was used to evaluate total reactive oxygen species content from A2780 ovarian tumor cells after mistletoe treatment. Mistletoe concentration 70μg/ml induces a significant toxic ROS-generating effect. These data indicates that the phenolic acids from mistletoe induce cell death by apoptosis on human tumor ovarian cell line, A2780.
  Zorita SCONTA , Dumitrita RUGINA , Floricuta RANGA , Adela PINTEA and Andrea BUNEA
  Different Romanian cultivars of Vaccinium corymbosum (Elliot, BlueCrop, and Duke) and Vaccinium myrtillius (Wild 1, Wild 2) were collected and analyzed for chlorogenic acid using High Performance Liquid Chromatography. Bluecrop cultivar was found to have the highest chlorogenic acid content (181.55 μg/100 g FW) among the cultivated blueberries analyzed, but the lowest values were obtained for Duke cultivar (97.84 μg/100 g FW). Both wild cultivars had high quantities of chlorogenic acid comparing to cultivate ones.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility